Estes M K
Division of Molecular Virology, Baylor College of Medicine, Houston, Texas, USA.
J Infect Dis. 1996 Sep;174 Suppl 1:S37-46. doi: 10.1093/infdis/174.supplement_1.s37.
The first candidate rotavirus vaccine was a live attenuated oral vaccine made by the classical empirical method of serial passage of virus in tissue culture cells. Current tetravalent vaccine candidates that are in the final stages of efficacy testing in the United States were made by genetic reassortment. This article briefly highlights how advances in the basic understanding of the molecular biology of rotaviruses have facilitated vaccine development. New approaches for second-generation vaccines and improvements in vaccine efficacy based on further exploitation of the tools and knowledge of rotavirus molecular biology and pathogenesis are discussed.
第一种轮状病毒候选疫苗是一种口服减毒活疫苗，它是通过病毒在组织培养细胞中连续传代的经典经验方法制备的。目前在美国处于效力测试最后阶段的四价候选疫苗是通过基因重配制备的。本文简要介绍了对轮状病毒分子生物学基本认识的进展如何推动了疫苗的研发。文中还讨论了第二代疫苗的新方法以及基于对轮状病毒分子生物学和发病机制的工具及知识的进一步利用而实现的疫苗效力改进。
